These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 6600985)

  • 21. In vitro and in vivo effect of deoxycoformycin in human T cell leukemia.
    Yu AL; Kung FH; Bakay B; Nyhan WL
    Adv Exp Med Biol; 1979; 122B():373-9. PubMed ID: 397762
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues.
    Plunkett W
    Ann N Y Acad Sci; 1985; 451():150-9. PubMed ID: 3907452
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro effects of adenosine deaminase inhibitors on lymphocyte mitogen responsiveness in the mouse.
    Ballow M; Pantschenko AG
    Cell Immunol; 1981 Oct; 64(1):29-43. PubMed ID: 6975175
    [No Abstract]   [Full Text] [Related]  

  • 24. Metabolic abnormalities of human adenosine deaminase deficiency reproduced in the mouse by 2'-deoxycoformycin, and adenosine deaminase inhibitor.
    Ratech H; Thorbecke GJ; Hirschhorn R
    Clin Immunol Immunopathol; 1981 Oct; 21(1):119-27. PubMed ID: 6268339
    [No Abstract]   [Full Text] [Related]  

  • 25. Prolongation of canine skin graft survival by deoxycoformycin.
    Epstein RB; Fey T; Sarpel S
    Transplantation; 1982 Feb; 33(2):208-9. PubMed ID: 7036476
    [No Abstract]   [Full Text] [Related]  

  • 26. Genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase and their implications for therapy of leukemias.
    Hirschhorn R; Ratech H
    Curr Top Hematol; 1983; 4():1-35. PubMed ID: 6413135
    [No Abstract]   [Full Text] [Related]  

  • 27. Exploiting biochemical differences in leukemia.
    Coleman MS; Grever MR
    Adv Exp Med Biol; 1984; 165 Pt B():315-20. PubMed ID: 6609538
    [No Abstract]   [Full Text] [Related]  

  • 28. Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors.
    Ho AD; Ganeshaguru K
    Klin Wochenschr; 1988 Jun; 66(11):467-74. PubMed ID: 2841534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
    Parks RE; Dawicki DD; Agarwal KC; Chen SF; Stoeckler JD
    Ann N Y Acad Sci; 1985; 451():188-203. PubMed ID: 3878117
    [No Abstract]   [Full Text] [Related]  

  • 30. Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia.
    Mitchell BS; Sidi Y; Hershfield M; Koller CA
    Ann N Y Acad Sci; 1985; 451():129-37. PubMed ID: 3878114
    [No Abstract]   [Full Text] [Related]  

  • 31. ATP depletion as a consequence of adenosine deaminase inhibition in man.
    Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.
    Dillman RO; Mick R; McIntyre OR
    J Clin Oncol; 1989 Apr; 7(4):433-8. PubMed ID: 2784491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo.
    Plunkett W; Alexander L; Chubb S; Loo TL
    Biochem Pharmacol; 1979; 28(2):201-6. PubMed ID: 426835
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition.
    Koller CA; Mitchell BS; Grever MR; Mejias E; Malspeis L; Metz EN
    Cancer Treat Rep; 1979; 63(11-12):1949-52. PubMed ID: 316725
    [No Abstract]   [Full Text] [Related]  

  • 35. Synergistic effect of 3'-deoxyadenosine N1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo.
    Svendsen KR; Overgaard-Hansen K; Frederiksen S
    Cancer Chemother Pharmacol; 1988; 21(1):35-9. PubMed ID: 3257721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The biochemical pharmacology of (2'-R)-chloropentostatin, a novel inhibitor of adenosine deaminase.
    Jackson RC; Leopold WR; Ross DA
    Adv Enzyme Regul; 1986; 25():125-39. PubMed ID: 2433905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levels of adenosine deaminase AMP deaminase, and adenylate kinase in cultured human lymphoblast lines: exquisite sensitivity of AMP deaminase to adenosine deaminase inhibitors.
    Fishbein WN; Davis JI; Winkert JW; Strong DM
    Biochem Med; 1981 Dec; 26(3):377-86. PubMed ID: 6277304
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
    Yu AL; Bakay B; Kung FH; Nyhan WL
    Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of PHA and NaI04 mitogenesis by the adenosine deaminase inhibitors erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) and 2-deoxycoformycin (2-dCF).
    Lum CT; Sutherland DE; Najarian JS
    Clin Immunol Immunopathol; 1979 Apr; 12(4):453-9. PubMed ID: 222523
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical pharmacology of deoxycoformycin.
    Major PP; Agarwal RP; Kufe DW
    Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.